Badreddin Edris Ph.D.
Net Worth

Last updated:

What is Badreddin Edris Ph.D. net worth?

The estimated net worth of Dr. Badreddin Edris Ph.D. is at least $17,611,757 as of 3 Dec 2024. He owns shares worth $9,847,008 as insider, has earned $5,143,949 from insider trading and has received compensation worth at least $2,620,800 in SpringWorks Therapeutics, Inc..

What is the salary of Badreddin Edris Ph.D.?

Dr. Badreddin Edris Ph.D. salary is $655,200 per year as Chief Operating Officer in SpringWorks Therapeutics, Inc..

How old is Badreddin Edris Ph.D.?

Dr. Badreddin Edris Ph.D. is 38 years old, born in 1987.

What stocks does Badreddin Edris Ph.D. currently own?

As insider, Dr. Badreddin Edris Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
SpringWorks Therapeutics, Inc. (SWTX) Chief Operating Officer 209,600 $46.98 $9,847,008

What does SpringWorks Therapeutics, Inc. do?

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Badreddin Edris Ph.D. insider trading

SpringWorks Therapeutics, Inc.

Dr. Badreddin Edris Ph.D. has made 11 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 8,034 units of SWTX stock worth $339,396 on 3 Dec 2024.

The largest trade he's ever made was exercising 32,000 units of SWTX stock on 25 Jan 2021. As of 3 Dec 2024 he still owns at least 209,600 units of SWTX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 8,034 $42.25 $339,396
Sale
Common Stock 11,966 $41.78 $499,939
Sale
Common Stock 3,080 $42.08 $129,591
Sale
Common Stock 4,620 $41.12 $189,956
Sale
Common Stock 12,300 $40.12 $493,415
Sale
Common Stock 385 $42.04 $16,184
Sale
Common Stock 3,651 $41.38 $151,067
Sale
Common Stock 4,192 $40.62 $170,287
Sale
Common Stock 11,772 $39.4 $463,840
Sale
Common Stock 32,000 N/A N/A
Sale
Common Stock 32,000 $84.07 $2,690,272

SpringWorks Therapeutics key executives

SpringWorks Therapeutics, Inc. executives and other stock owners filed with the SEC: